Volido PASNCT07918443
Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VI
StatusNot Yet Recruiting
PhaseNot applicable
SponsorCroma-Pharma GmbH
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: Baseline through Week 24 after the last injection
Secondary (9)
Injection site reactions
Subject-reported pain
Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on the evaluating investigator's live assessment
Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on independent photographic reviewers' assessment
Change from baseline in midface volume deficit measured by the 5-point Midface Volume Deficit Severity Scale (MVDSS), based on the evaluating investigator's live assessment
Show 4 moreShow less
Global aesthetic improvement based on the 5-point modified Global Aesthetic Improvement Scale (mGAIS)
Subject satisfaction with treatment outcome and appearance based on the FACE-Q™ "Satisfaction with Outcome" and "Satisfaction with Cheeks" questionnaires
Injection volume required to achieve optimal aesthetic correction
Change from baseline in nasolabial fold severity measured by the Nasolabial Fold Severity Rating Scale (NLF-SRS) based on the evaluating investigator's live assessment
Arms and interventions
saypha® ChIQ™Experimental
Participants receive treatment with saypha® ChIQ™ for correction of moderate to severe midface volume deficit. An optional touch-up treatment may be administered approximately 2 weeks after the initial treatment if clinically indicated.
Devices: Crosslinked hyaluronic acid dermal filler with lidocaine